Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study
G. Frasci(Radiation Oncology Institute), Giuseppe Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), A. Contu(Ente Ospedaliero Ospedali Galliera), Vito Lorusso(Istituto Tumori Bari), G Pusceddu(Institute for Experimental Endocrinology and Oncology), G.P. Nicolella(Radiation Oncology Institute), Vittorio Mascia(Institute for Experimental Endocrinology and Oncology), E Micillo(Medical Center Hospital), R Cioffi(Medical Center Hospital), Michèle Natale(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), B. Massidda(Policlinico Universitario di Catania), Luigi Manzione, Giuseppe De Cataldis(Radiation Oncology Institute), Pasquale Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M Belli(Radiation Oncology Institute), Nicola Panza(Radiation Oncology Institute), Francesco Carpagnano(Institute for Experimental Endocrinology and Oncology), Mario De Lena(Radiation Oncology Institute), Luigi Maiorino(Medical Center Hospital)
Cited by 54
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
|JNCI Journal of the National Cancer Institute|2005|154
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108